Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Alectinib in Hepatic Impairment
NCT02621047Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Roche. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity and 1 more. Started Dec 2015; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02621047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621047.